Kantarjian et al53 assessed the efficacy and protection of dasatinib, as in contrast with imatinib, for the very first-line cure of CML-CP. 5 hundred and nineteen people with freshly diagnosed CML-CP were randomly assigned to receive dasatinib at a dose of 100 mg as soon as every day (259 patients) https://tommyx073bsh1.blogacep.com/profile